Equities
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)342.20
  • Today's Change-2.70 / -0.78%
  • Shares traded7.93k
  • 1 Year change+41.11%
  • Beta0.6307
Data delayed at least 15 minutes, as of Feb 02 2023 11:17 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

argenx SE, formerly arGEN X BV, is the Netherlands-based biopharmaceutical company. It creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes: ARGX-110, an antibody for heme malignancies and solid tumors, which modulates functions of tumor such as cell proliferation and survival; ARGX-111, an antagonist of c-Met, a receptor tyrosine kinase involved in cell proliferation, angiogenesis and metastasis in multiple solid tumors; ARGX-112, an antigen which targets atopic dermatitis by neutralization of IL-20 and IL-22 (interleukin) mediated signaling through blockade of their common receptor, among others.

  • Revenue in EUR (TTM)238.97m
  • Net income in EUR-827.00m
  • Incorporated2008
  • Employees650.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Qiagen NV2.03bn421.83m10.24bn6.20k24.223.3316.845.061.831.838.7913.300.35452.386.40336,031.507.383.699.284.2864.7365.5420.8311.681.6223.130.4076--20.3910.9742.7144.8417.07--
Croda International Plc2.35bn800.66m10.94bn6.14k13.684.1111.644.665.085.0814.8916.910.56862.714.97339,511.0019.5211.1722.6313.1648.2243.7134.3316.392.2524.360.320261.7835.918.7359.1310.288.535.70
BioMerieux SA3.46bn552.00m11.07bn13.08k20.083.2213.783.204.664.6629.2029.030.75232.235.93264,606.9011.929.7815.1813.1357.4255.4715.8512.691.3260.640.144114.148.279.9348.6427.404.4820.59
Eurofins Scientific SE6.86bn823.70m12.57bn61.00k15.842.678.811.834.123.2134.2724.420.724831.284.92118,238.709.057.6611.399.7325.1323.5212.4911.801.2510.160.412416.2223.5121.5050.0739.8821.0737.97
UCB SA5.92bn887.00m14.35bn8.56k15.971.5710.952.424.624.6230.8146.940.40371.824.79691,975.306.057.397.389.3073.0974.3414.9916.730.82836.690.252828.568.046.8544.1314.2129.002.48
argenx SE238.97m-827.00m18.91bn650.00------79.13-15.90-15.904.50--------367,652.60---20.19---22.8683.75---346.06-191.43---7.70----1,105.7398.1632.90--163.70--
Genmab A/S1.61bn759.96m23.57bn1.56k31.016.50--14.6385.7185.71181.62408.670.4385--2.949,890,264.0020.6818.8722.6820.07----47.1742.62----0.0230.00-16.1136.10-36.7820.4450.07--
Merck KGaA21.79bn3.47bn23.59bn63.72k22.872.814.491.087.987.9850.0865.000.45981.905.18361,073.307.365.009.246.6062.3563.1716.0012.090.858826.730.289.1612.285.5653.7513.4010.889.04
Data as of Feb 02 2023. Currency figures normalised to argenx SE's reporting currency: Euro EUR

Institutional shareholders

20.74%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 01 Mar 20221.98m3.58%
Federated Global Investment Management Corp.as of 18 Oct 20221.65m2.98%
Wellington Management Co. LLPas of 01 Mar 20221.55m2.79%
Baillie Gifford & Co.as of 01 Mar 20221.40m2.53%
Norges Bank Investment Managementas of 31 Dec 20211.20m2.18%
RTW Investments LPas of 08 Jul 20221.06m1.91%
BlackRock Fund Advisorsas of 05 Jan 2023911.92k1.65%
Bellevue Asset Management AGas of 30 Sep 2022892.50k1.61%
Polar Capital LLPas of 30 Nov 2022447.95k0.81%
BlackRock Advisors (UK) Ltd.as of 05 Jan 2023384.51k0.70%
More ▼
Data from 31 Dec 2021 - 31 Dec 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.